Trending Now
- “The successful launch of the Vikram-1 rocket is a historic achievement. India’s youth have made the nation proud.” – PM Modi
- “A decision on an alliance with TVK will be announced at the appropriate time, closer to the local body elections. We welcome TVK’s anti-corruption initiatives.” – G.K.Vasan
- “We will not attend any INDIA alliance meetings or participate in any programmes coordinated by the Congress.” – DMK MP T.R.Baalu
- France’s Mbappé won the FIFA World Cup Golden Boot for the second consecutive time after finishing as the tournament’s top scorer.
- “We condemn the attack on students in Delhi. NEET is against students.” – Minister Nirmal Kumar
Businesswire
Eurofins Announces Acquisition of Assets of Gomti Life Sciences
February 5, 2020
Business Wire IndiaEurofins, through Eurofins Advinus, acquires all assets of Gomti Life Sciences Private Limited through a Business Transfer Agreement. The assets include a fully equipped state-of-the-art manufacturing facility located in Bidadi Industrial Area, Bangalore, India, with cGMP pilot plant, intermediate area and ISO class 8 clean rooms and a total reactor capacity of about 45 KL.
With this acquisition, Eurofins Advinus will be able to manufacture RSMs, intermediates, APIs and NCEs. The company can now support drug substance requirements from multi kilogram to MT scale for Toxicology studies, clinical trials and launch quantities.
Rajiv Malik, MD of Eurofins Advinus Limited commented: This acquisition could be a game changer for Eurofins Advinus as it enables the group to enter clinical development and commercial supply part of the Pharma R&D value chain through cGMP API supplies of NCEs. This addition is also a part of a larger foray of the Eurofins group into CDMO / CRAMS market.
Source: Businesswire
With this acquisition, Eurofins Advinus will be able to manufacture RSMs, intermediates, APIs and NCEs. The company can now support drug substance requirements from multi kilogram to MT scale for Toxicology studies, clinical trials and launch quantities.
Rajiv Malik, MD of Eurofins Advinus Limited commented: This acquisition could be a game changer for Eurofins Advinus as it enables the group to enter clinical development and commercial supply part of the Pharma R&D value chain through cGMP API supplies of NCEs. This addition is also a part of a larger foray of the Eurofins group into CDMO / CRAMS market.
Source: Businesswire
